Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chlorotrianisene is a synthetic nonsteroidal estrogen that functions as an orally active estrogen receptor modulator. It acts as a prodrug, mimicking the action of natural estrogens by binding to and activating estrogen receptors, leading to various physiological responses. While primarily exhibiting estrogenic effects, it also possesses some antiestrogenic activity, classifying it as a selective estrogen receptor modulator (SERM). Additionally, it has been shown to inhibit cyclooxygenase-1 (COX-1) and platelet aggregation. Historically, Chlorotrianisene was used for hormone replacement therapy, menopausal symptoms, and certain types of breast and prostate cancer, but its use has since been discontinued.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chlorotrianisene.